Advanced Filters
noise

Migraine (Adult) Clinical Trials

A listing of Migraine (Adult) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 120 clinical trials

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening …

18 - 100 years of age Both Phase 2
J Jianhua Wang, MD, PHD

Clinical Applications of Advanced Ophthalmic Imaging

The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase …

18 - 99 years of age Both Phase N/A
H Hendrika Bootsma

Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome

The ANISE-II study is a randomized, double-blind, placebo-controlled phase IIa proof-of-concept trial. Thirty patients with primary Sjögren's syndrome (pSS) are randomized in a 2:1 ratio to either anifrolumab or placebo treatment for 24 weeks. Main inclusion criteria are fulfilment of the ACR/EULAR classification criteria for pSS, disease duration of ≤10 …

18 - 100 years of age Both Phase 2
L Lise Laclautre

Ultrasound Characteristics of the Salivary Glands in Patients With Rheumatoid Arthritis

The prevalence of Sjogren's syndrome (SS) in rheumatoid arthritis (RA) patients varies from 3.5 to 31%. Between 30% and 90% of patients with (RA) have dry eye and/or mouth syndrome. To date, no studies have assessed whether RA patients have echostructural changes in their salivary glands suggestive of SS and …

18 - 100 years of age Both Phase N/A
A Antonio Carroccio, PHD

Wheat-free Diet in the Treatment of Sjogren's Syndrome

Recent data show that some foods can increase intestinal mucosa permeability and immune activation of subjects with gastrointestinal (GI) symptoms. Wheat seems the most frequent food which activates this inflammatory response and can cause both GI and extra-intestinal symptoms. Patients suffering from wheat-related troubles, in absence of celiac disease diagnosis, …

18 - 65 years of age Both Phase N/A
Y Yongxian Hu, PhD

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

- 100 years of age Both Phase N/A
H Hongmei Song, Doctor

Belimumab After Rituximab in Resistant Primary Juvenile SS

The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome. Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients Researchers will compare the disease activity before and …

5 - 18 years of age Both Phase 4
S SAMI XI, dr

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or CD19 or both sequentially in the treatment of Relapsed/ Refractory Autoimmune Disease such as Sjogren's Syndrome or Systemic Lupus Erythematosus and other Autoimmune Disease.

21 - 90 years of age Both Phase 1/2
H Huji Xu, Doctor

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.

18 - 65 years of age Both Phase N/A
L Liyun Zhang, MD

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease

18 - 100 years of age Both Phase 1

Rewrite in simple language using AI